CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Breast cancer is the most common form of cancer among women. For patients candidated for adjuvant chemotherapy and endocri...
Phase 3
Roma, RM, Italy and 73 other locations
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...
Phase 1, Phase 2
Rome, Italy and 71 other locations
This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abn...
Phase 2
Roma, Italy and 36 other locations
This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast...
Phase 2
Roma, Italy and 61 other locations
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Roma, Lazio, Italy and 324 other locations
medicines for the potential treatment of advanced or metastatic breast cancer.This study is seeking participants who have breast...
Phase 1, Phase 2
Roma, Lazio, Italy and 40 other locations
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Rome, Italy and 147 other locations
medicines for the potential treatment of advanced or metastatic breast cancer.This study is seeking participants who have breast...
Phase 1, Phase 2
Roma, Lazio, Italy and 43 other locations
of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced Breast...
Phase 3
Roma, Italy and 105 other locations
how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast...
Phase 3
Roma, Italy and 118 other locations
Clinical trials
Research sites
Resources
Legal